Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.

This is an interventional, prospective, national, multicenteric, randomized, open-label, controlled clinical study comparing two arms: Control arm taking the standard of care Versus Intervention arm (standard of care + Respicure®).

A total of 480 patients (160 in each group of pathology i.e Asthme, COPD and long COVID, distributed through 8 centers resulting in 20 patients/center for each group of pathology). The administration of the study product is by randomaisation.The data will be collected during 5 visits for the two arms as following:

• Visit V1 on D0: inclusion, signature of informed consent and implementation of the RESPIRE DZ protocol with delivery to patients of a one-month supply of Respicure® for the intervention arm,
• Intermediary visit on D15: face-to-face and/or by telephone to assess safety after the use of Respicure® for the intervention arm.
• Visit V2 on D30: follow-up visit with delivery to patients of a one-month supply of Respicure® for the intervention arm,
• Visit V3 on D60: follow-up visit with delivery to patients of a one-month supply of Respicure® for the intervention arm,
• Visit V4 at D90:follow-up visit at the end of the use of the study product,
• Visit V5 at D180: follow-up and end-of-study visit.

• Inclusion Criteria for Asthma patients:

• Male, female, aged ≥19.
• Being able to provide written informed consent before the study.
• Patient with partially controlled asthma: Assessment of asthma control over the month preceding the use of Respicure ® by a symptomatic assessment (Tick one or two symptoms):

• 1 Daytime symptoms more than twice a week, 3. 2 One or more nocturnal awakenings, 3. 3 Need for rescue medication more than twice a week, 3. 4 One or more activity limitations

• Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc…
• Inclusion Criteria for COPD patients:

• Male, female, ≥40 years old
• Being able to provide written informed consent before the study.
• Patient with COPD stage A, B, C or D in stable condition with no exacerbations in the past 4 weeks.
• Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc…
• Inclusion Criteria for long covid patients:

• Male, female, aged ≥19.
• Being able to provide written informed consent before the study.
• Patients followed for respiratory symptoms linked to long Covid (symptoms for more than 12 weeks).

Exclusion criteria

• Patient with severe asthma (for asthma groupe only)
• Prior use of Respicure®.
• Concomitant use with the following products: cytochrome P450 3A4 substrate drugs (e.g. statin, antifungals and fexofenadine), antibiotics (quinolones), immunosuppressants (cyclosporine) and glycoprotein P substrate drugs, e.g. antifungal and antiarrhythmic .
• Hypersensitivity to any of the ingredients.
• Hypersensitivity to peanuts.
• Concomitant intake of a product containing one or both of the active ingredients (resveratrol/quercetine).
• Pregnancy/ lactation.
• People who need to undergo surgery.
• Participation in another clinical study within the previous 30 days.
• Patient with asthma-COPD overlap syndrome or any other respiratory disease such as pneumonia, tuberculosis, pulmonary embolism, etc.
• Hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis or uterine fibroids.
• Patients requiring admission to intensive care and/or requiring respiratory assistance.
• Patients requiring anticoagulant treatment at curative doses.